Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin: Results From a Randomized Double Blinded Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 116
- 试验地点
- 1
- 主要终点
- Adverse effects
研究概览
简要总结
To compare the efficacy and effect on glycemic control of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents using metformin
详细描述
To observe the efficacy, effect on glycemic control, impact on BMI and incidence of adverse effects of Dulaglutide and to compare it to Liraglutide in individuals aged thirteen to eighteen who have Type 2 diabetes mellitus and are obese.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 19 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 Diabetes Mellitus
- •Taking metformin
- •Male or female
排除标准
- •Non obese
- •Not taking metformin
- •Taking other injectable diabetic medications
研究组 & 干预措施
Group DUL
Group taking Dulaglutide injections
干预措施: Dulaglutide (Drug)
Group LIR
Group taking Liraglutide injections
干预措施: Liraglutide (Drug)
结局指标
主要结局
Adverse effects
时间窗: 24 weeks for the duration of the study
Recording of adverse effects
Glycemic level
时间窗: 24 weeks for the duration of the study
HbA1c
BMI
时间窗: 24 weeks for the duration of the study
BMI measurements using weight and height measurements (anthropometric)
次要结局
未报告次要终点
研究者
Dr Zainab Khan
Chief Resident
Corporacion Parc Tauli